Risks and benefits from CDK inhibitors for advanced HR+ Her 2- breast cancer

Ann Oncol. 2017 Dec 1;28(12):3099-3100. doi: 10.1093/annonc/mdx530.
No abstract available

Publication types

  • Letter
  • Meta-Analysis

MeSH terms

  • Aminopyridines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzimidazoles / administration & dosage
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / metabolism*
  • Cyclin-Dependent Kinases / antagonists & inhibitors
  • Estradiol / administration & dosage
  • Estradiol / analogs & derivatives
  • Female
  • Fulvestrant
  • Humans
  • Letrozole
  • Nitriles / administration & dosage
  • Piperazines / administration & dosage
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / therapeutic use*
  • Purines / administration & dosage
  • Pyridines / administration & dosage
  • Randomized Controlled Trials as Topic
  • Receptor, ErbB-2 / biosynthesis*
  • Receptors, Estrogen / biosynthesis
  • Risk Assessment
  • Triazoles / administration & dosage

Substances

  • Aminopyridines
  • Benzimidazoles
  • Nitriles
  • Piperazines
  • Protein Kinase Inhibitors
  • Purines
  • Pyridines
  • Receptors, Estrogen
  • Triazoles
  • Fulvestrant
  • Estradiol
  • abemaciclib
  • Letrozole
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Cyclin-Dependent Kinases
  • palbociclib
  • ribociclib